



## The Correlation Between Microsatellite Instability and the Features of Sporadic Colorectal Cancer in Sample of Iraqi Patients

Basim Mohammed Hanon<sup>1</sup>, Nidhal Abd Al-Mohaimen Mohammad<sup>2</sup> and Aqeel Shakir Mahmood<sup>3</sup>.

<sup>1</sup> Department of Microbiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq  
basimdr28@yahoo.com

<sup>2</sup>Department of Microbiology, College of Medicine, Al-Nahrain University, department of medical biotechnology, college of applied biotechnology, Baghdad, Iraq  
dr.nidhalmohammed@yahoo.com

<sup>3</sup>Baghdad university –college of medicine, Baghdad, Iraq, Chairman of the Scientific Council of gastrointestinal surgery at the Iraqi Council for Medical Specialties  
aqeel.shakir@yahoo.com

### ABSTRACT

Microsatellite instability (MSI) is a mutational signature found in colorectal carcinoma (CRC), it represents about 12% in non inherited CRC. We aimed in this study to correlate between MSI and sporadic CRC Iraqi patients. A total of 47 patients with colorectal carcinoma were enrolled in this study, among these patients 26 (55%) males and 21(45%) females, with a range age from 37 years to 72 years, mean age (54.5 year). Microsatellite marker amplifications were performed as singleplex PCR reactions. Results were divided into three groups, group 1 with MSI<sub>high</sub> were constituted a frequency of 17 (36.17 %), and group 2 with MSS (16) (34.04 %) and group 3 with MSI<sub>low</sub> the frequency( 14 ) (29.78 %). MSI<sub>high</sub> was expressed in high percentage (38.09%) in women compared with male( 34.61%),while its relation to age, results indicated that age group ( $\leq 50$  years) showed high percentage (37.93%) compared with Group 1( $\geq 50$  years) (33.33%) and the relation of MSI with morphological feature of the specimens showed that poorly differentiated CRC specimens showed the highly percentage ( 47.07% ) when compared with well and moderately differentiated cases. The mucinous type of CRC revealed 100% percentage for MSI compared with nonmucinous ( 27.65%) with significant difference. High frequency of MSI was shown in right site (52.94%) with significant difference compared with MSI L and MSS. In conclusion: This study showed that there were a close association between MSI with female patients, old patients, and right site, mucinous and poorly differentiated CRC.

### Indexing terms/Keywords

CRC, MSI, PCR.

### Academic Discipline And Sub-Disciplines

Immunogenetics.

### Subject Classification

Tumor Immunology.

### Type (Method/Approach)

PCR-Experimental.

# Council for Innovative Research

Peer Review Research Publishing System

Journal: JOURNAL OF ADVANCES IN BIOTECHNOLOGY

Vol .4, No 1.

[www.cirjbt.org](http://www.cirjbt.org) , [jbteditor@gmail.com](mailto:jbteditor@gmail.com)



## INTRODUCTION

Colorectal cancer (CRC), is one of the most frequent malignancies in the Western world. Worldwide, approximately 1, 2 million people developed colorectal cancer in 2008 and the disease related mortality was about 36% (1) (2) The disease affects slightly more men than women and sporadic colon cancer is considered to be a disease of the elderly with a median age at diagnosis of 70 years (3).

Microsatellites are repeated DNA sequences, usually 1 to 10 nucleotides long, present throughout the genome. Instability is mostly characterized by single base-pair insertions or deletions in these repeat loci, causing widespread genomic instability due to the failure of the cell's mismatch repair (MMR) mechanism (4) (5) .A recognizable clinicopathological profile of MSI tumors has been established from clinical studies. CRC displaying MSI tend to be right sided and diagnosed at lower pathological stages compared with MSS cancers. The age distribution of MSI cancers follows a u shaped distribution, and sporadic MSI cases are generally diagnosed in older patients (>70 years of age) whereas familial cases are younger (<50 years of age)(6). Since many colon cancers demonstrate frame shift mutations at a small percentage of microsatellite repeats, the designation of a colon tumor as showing microsatellite instability depends on the detection of at least two unstable loci out of five from a panel of loci that were selected by a National Cancer Institute consensus conference (4).

MSI is also found in ~80% of adenomas of variable size from HNPCC patients, compared to 12-18% of the sporadic tumors (7). MSI tumors are more often located in the proximal colon, poorly differentiated, and of a mucinous, or signet ring, histological type (8). Another common finding in MSI CRC is the presence of tumor-infiltrating T cells (9). MSI tumors have often been associated with a better patient prognosis compared with MSS (1). Three classes of MSI have been defined: MSI-H (MSI-high), MSI-L (MSI-low) and MSS (microsatellite stable) that are distinguished by the degree of instability found in a panel of five reference <sup>markers</sup>. The panel recommended by the National Cancer Institute consists of two mononucleotide (BAT25 and BAT26) and three dinucleotide (D5S346, D2S123 and D17S250) repeating units. MSI-H tumors exhibit instability in two or more markers whilst MSI-L tumors have instability in only one marker. Tumors lacking apparent instability can, however, be either MSI-L or MSS and so may require the analysis of additional markers for confirmation (4). **This study aims to identify for the first time in Iraq, types of MSI in sample of CRC Iraqi patients.**

## Material And Methods

**Specimens**, were collected from GIT center, Baghdad hospital and private hospitals. In the period from 1-4-2013 to 1-2-2014, which more than three biopsies were obtained from grossly tumor areas, and surgery specimens obtain after surgery tumor removal both specimens from surgery and biopsies were fixed with 10% buffered formalized saline, for preparation the paraffin embedded tissue blocks to histological molecular diagnostic methods DNA extraction from FFPE.

**Histological evaluation specimens**, slides from fixed paraffin embedded tissue blocks were stained with haematoxylin – eosin stain and subsequently evaluated by an experienced pathologist.

**DNA extraction from FFPE** ,QIAamp DNA FFPE tissue kit, (50) reaction Mineute columns, kits. DNA evaluation by Nano drop For an A260/A280 value of 1.5, the percentage of protein in the DNA preparation, for good PCR-SSP results, DNA is required with an A260/A280 quotient of 1.6 or greater. The sections of tumor tissue should contain more than 50% of neoplastic cells (14) in order to avoid false negatives. Microsatellite marker amplifications are performed as singleplex PCR reactions using DNA from tumor tissue. In accordance to the recommendations by the NCI. The validated five microsatellite panel is tested first. This latter panel is currently adopted by the institutions of the IMPACTS group in a diagnostic setting (6)

## PCR PreMixAccuPower®

**Stability:** the powerful technology for convenient and easy to perform DNA amplification. It contains DNA polymerase, dNTPs, a tracking dye and reaction buffer in a premixed format, freeze-dried into a pellet. 25/100 bp Mixed DNA Ladder is specially designed for determining the size of double strand DNA from 25 to 2,000 base pairs. The DNA Ladder consists of 17 double strand DNA fragments ranging in size from 25 to 200 bp in 25 bp increments, the PCR reaction was performed in a final volume of 50 ml, containing:

0.5 µl b-globin both forward primer, reverse primer 30 pmol/ml. 0.3 pmol/µl final, 1 µl of diluted sample DNA, 20 µl mister mix, H<sub>2</sub>O to volume, Overlay the reaction mixture with 20 ml of mineral oil.

Thermal cycling: 94°C 10" + 5 × (94°C 60", 52°C 60", 72°C 60") + 35 × (94°C 30" 52°C 30" 72°C 30") + 72°C 5'.

Gel visualization: mix 10 ml of PCR product with 2 µl of 6× loading buffer; load on a 2% agarose gel prepared with 1× TBE containing 0.5 mg/ml ethidium bromide. Run at 80 V constant until bromophenol blue reaches 1/2 of the gel. Inspect under a UV source. A single band should be visible in the sample.

Thermal cycling: 94°C 10' + 5 × (94°C 60", 55°C 60", 72°C 60") + 35 × (94°C 30" 55°C 30" 72°C 30") + 72°C 5'.in all genes with same add of PCR reaction of b-globin.

## Internal control

Since DNA extracted from FFPE can be variably degraded and may contain PCR inhibitors, we suggest performing a preliminary quality control to test if sample. DNA is suitable for MSI and to determine the optimal quantity for amplification. For this purpose, a 167 bp fragment of the b-globin gene is amplified. Since b-globin gene is present in all the cells (it



never undergoes deletions) and is not polymorphic, it is a suitable target for the control PCR.(15) The size of the amplified fragment (167 bp) reflects the length of the largest PCR product that can be obtained.

Positive control for b-globin: DNA from normal human lymphocytes, 50 ng/ml.( 16)

### PCR primers

**Primers:** Lyophilized primers should be dissolved in a small volume of distilled water or to make a concentrated (e.g. 300 pmol/ $\mu$ l) stock solution. Prepare small aliquots of working solutions containing 30 pmol/ml to avoid repeated thawing and freezing.

Marker Name	Genomic Position	Sequences (5'–3')	T °m	(bp)
b-globin	11p15.5	F: ACACAACCTGTGTTCACTAGC R: GAAAATAGACCAATAGGCAG	53.4 53.9	167

Marker Name	Genomic Position	Sequences (5'–3')	T °m	(bp)
D2S123	2p16-2p16	F: ACATTGCTGGAAGTTCTGGC R: CCTTTCTGACTTGGATACCA	62.6 57.5	121–141
D5S346	5q21-5q22	F: ACTCACTCTAGTGATAAATCGGG R: AGCAGATAAGACAGTATTACTAGTT	58.7 52.1	96–122
D17S250	17q11.2-17q12	F: GGAAGAATCAAATAGACAAT R: GCTGGCCATATATATATTTAAACC	50.6 57.2	151–169
BAT25	4q12-4q12	F: TCGCCTCCAAGAATGTAAGT R: TCTGCATTTTAACTATGGCTC	59.7 57.0	124
BAT26	2p16.3-2p16.3	F: TGACTACTTTTGACTTCAGCC R: AACCATTCAACATTTTTAACCC	57. 59.0	121

### Statistical methods:

The significance of differences in proportions was analyzed by the chi-square test. Fisher's exact test was used when there was a cell with a number less than 5. Entry of data into the computer and the chi-square and Fisher exact tests were performed with SPSS version 15 and P values equal or less than 0.05 were considered statistically significant.

### Results

#### Sex and age distribution

Total of 47 patients with colorectal carcinoma were collected among of these patients 26(55%) males and 21(45%) females figure (1), with a range age from 37 years to 72 years, mean age (54.5 year), with 1:1.2 ratio between female and male. The patients' age were classified into two group first  $50 \geq$  years (38.29%), second group  $50 \leq$  years 29 (61.70%) fig. (2).




Figure 1. The sex distribution of CRC



Figure 2 the age group frequency in CRC

**Morphological differentiation**, as regards with grades of colorectal carcinoma, it was observed that (14.89%) cases of well differentiated, (53.19%), moderate differentiated and (31.91%) poorly differentiated Figure 3.

**Site of tumor**: Patients with CRC were classified according to the site of tumor location as shown in figure (4), right site consistent (51.06 %) of all cases and patients, with left site (36.17 %) and (12.76 %) in the rectum from all cases.



Figure 3. The morphological distribution of CRC



Figure4. Site of tumor distribution in CRC.

### MSI Distributions

Microsatellite marker amplifications were performed as singleplex PCR reactions. The results were divided in to three groups, group 1 with MSI<sub>high</sub> were constituted a frequency of 17 (36.17 %), and group 2 with MSS (16) (34.04 %) and group 3 with MSI<sub>low</sub> the frequency( 14 ) (29.78 %) figure.5.

As shown in the figure 6, the internal control B-globin was appeared in the region 167bp while D5S346 reviled at the region 122 bp figure 7, BAT26 in 121bp figure 8, BAT25 in 124 bp figure 9, D17S250 in 169bp figure 10 and D2S123 in 141bp figure 11.

### MSI Related With Frequency of Microsatellite Panel Genes.

MSI<sub>high</sub> and MSI<sub>low</sub> showed close associated with frequency of the microsatellite genes panel in all cases, the highly percentage was show in BAT25 48.93%, while 44.68% in both BAT26, D5S346, 19.14% in D17S250 and 25.23% in D2S123 12(47) table 1.




Figure 5. MSI (high, low and stable) in groups of CRC patients.




Fig. 7 Gel electrophoresis (2% agarose, 7 v/cm<sup>2</sup>, 1. hrs) of PCR positive products for D5S346 was appeared in 122 bp, 25/100bp DNA ladder was used.




Fig. 6 Gel electrophoresis (2% agarose, 7 v/cm<sup>2</sup>, 1. hrs) of PCR positive products for b-globin 167bp , 25/100bp. DNA ladder was used




Fig. 9 Gel electrophoresis (2% agarose, 7 v/cm<sup>2</sup>, 1. hrs) of PCR positive products for BAT25 was shown in 124bp, 25/100bp DNA ladder was used




Fig. 8 Gel electrophoresis (2% agarose, 7 v/cm<sup>2</sup>, 1. hrs) of PCR positive products for BAT26 was shown in 121bp 25/100bp DNA ladder was used.




Fig. 11 Gel electrophoresis (2% agarose, 7 v/cm<sup>2</sup>, 1. hrs) of PCR positive products for D2S123 was shown in 141bp, 25/100bp DNA ladder was used.




Fig. 10 Gel electrophoresis (2% agarose, 7 v/cm<sup>2</sup>, 1. hrs) of PCR positive products for D17S250 was shown in 169, 25/100bp DNA ladder was used



**Table 1 the Genes Frequency of Microsatellite Panel in Both MSI<sub>High</sub> and MSI<sub>Low</sub>**

NO	MSI status	Total NO/%	MSI <sub>high</sub> NO/%	MSI <sub>low</sub> NO/%	MSS NO/%	All cases	P value
1.	BAT26	21(44.68)	17(36.17)	4(8.51)	26(55.31)	47	P0.0004
2.	BAT25	23(48.93)	17(36.17)	6(12.76)	24(51.06)	47	0.005
3.	D5S346	21(44.68)	17(36.17)	4(8.51)	26(55.31)	47	P0.0004
4.	D17S250	9(19.14)	9(19.14)	0(0)	38(80.85)	47	P0.000
5.	D2S123	12(25.53)	12(25.53)	0(0)	35(74.46)	47	P0.0000

**MSI related with sex**, MSI<sub>high</sub> was significantly associated with female patients that constitute 38.09%, while male patients account to 34.61% while, but male patients showed the high percentage 34.61% for expression of MSI<sub>low</sub>. MSS was shown to be expressed in high percentage in female patients 38.09% Table 4-2, but with no significant difference.

**Table 2 The Sex Distribution in MSI<sub>High</sub>, MSI<sub>Low</sub> and MSS.**

Sex	MSI <sub>high</sub> NO/%.	MSI <sub>low</sub> NO/%.	MSS NO/%.	Total number	P value	X <sup>2</sup> Df=2
Male	9(34.61)	9(34.61)	8(30.76)	26	0.944	0.115
Female	8(38.09)	5(23.80)	8(38.09)	21	0.526	1.286
P-	0.732	0.131	1.000	47		Df=2

### MSI Associated With Age

Patients were classified according to age in two groups, Group 1 which included patients with age less than 50 years was showed high percentage of expression for MSI<sub>low</sub> 38.33%, followed by the MSI<sub>high</sub> (33.33%). The group 2 high associated with MSI<sub>high</sub> and MSS with 37.93%, table 4-3 with no significant difference.

**Table 3 MSI Associated with Age Group Patients of CRC**

Age group	MSI <sub>high</sub> NO/%.	MSI <sub>low</sub> NO/%.	MSS NO/%.	Total	X <sup>2</sup> = 1.213
Group 1 ≥50	6(33.33)	7(38.88)	5(27.77)	18	
Group 2 ≤50	11(37.93)	7(24.13)	11(37.93)	29	
	17	14	16	47	P= 0.5452

**MSI related with morphological feature**, MSI<sub>high</sub> showed close associated with poorly differentiated cases 47.07%, followed by moderately differentiated 35.26% and the showed well differentiated 17.64% table 4-4 but no significant difference between grade and MSI<sub>high</sub> and <sub>low</sub> and significant with MSS.

**Table 4 Morphological Distribution in MSI<sub>High</sub>, MSI<sub>Low</sub> and MSS in CRC.**

Grade	MSI <sub>high</sub> NO/%	MSI <sub>low</sub> NO/%	MSS NO/%	Total	P value	X <sup>2</sup> Df=2
well	3(17.64)	2(14.28)	2(12.5)	7	0.807	0.429
moderate	6(35.26)	7(50)	12(75)	25	0.156	3.720
poor	8(47.05)	5(35.17)	2(12.5)	15	0.067	5.400
P-	0.187	0.131	0.0001			
X <sup>2</sup> Df=2	3.353	4.071	18.750		0.214 Df=4	5.807

MSI related with muosinous and nonmuosinous CRC, MSI close association with mucinous cases of CRC showed high percentage of expression 100%, compared with nonmucinous AC with 27.65% Figure 4-12, with highly significant drffrence.

**Figure 4-12. MSI related with Muosinous and nonmuosinous CRC.**




MSI related with site of tumor, MSI<sub>high</sub> was highly expressed in patients with right site colon location (52.94%), followed by left site (35.29%) where an rectum showed lower expression site frequency percentage (11.76%), as show in table 4-5, with significant deffrence in both MSI<sub>high</sub> and MSI<sub>low</sub>.

**Table 5 Realted of Site of Tumor With MSI<sub>Low</sub>, MSI<sub>Low</sub> And MSS**

Site	MSI <sub>high</sub>	MSI <sub>low</sub>	MSS	Total	P value	X <sup>2</sup>
Right	9(52.94)	7(50)	8(50)	24	0.829	0.375
Left	6(35.29)	6(42.85)	5(31.25)	17	0.916	0.176
Rectum	2(11.76)	1(7.15)	3(18.75)	6	0.472	1.500
Df=2	17	14	16	47		
P-value	0.038	0.036	0.168		Df=4	
X <sup>2</sup>	6.529	6.643	3.563		0.893	1.111



**MSI<sub>high</sub> repeated gene**, MSI<sub>high</sub> showed the expressed 4 genes in this panale high frequency with 52.94% and following by 3 genes with 47.05%, and 5 genes revealed 17.64% figure 4- 13 with significant difference  $p = 0.012$ .



**Fig. 13. MSI<sup>High</sup> Repeated Genes In Patient Of CRC.**

## Discussion

MSI the hallmark of hereditary nonpolyposis colorectal cancer (HNPCC), previously known as Lynch syndrome, occurs in approximately 15–25 % of sporadic tumors of the colorectum and other organs as well.(17)

CRC is a heterogeneous disease and MSI may serve as a predictive marker for the response of patients with CRC to specific therapies and as a guide to the selection of optimal therapy.(18)

In this study detection microsatellite colorectal cancer pathway, first MSI<sub>high</sub> with percentage (36.17 %), and second group MSI<sub>low</sub> was recorded in (29.78 %), while the third group MSS was shown in (34.04 %).

This result was agreement with some and different from other, in study of,(29) was demonstrated (43%) microsatellite instability<sub>high</sub> (52.94%) were microsatellite stable (MSS) and 2(3.9%) were MSH<sub>Low</sub> .

MSI markers on paraffin-embedded surgically resected tissues sporadic Iranian colorectal cancer patients MSI analysis revealed MSI-H (26.9%), MSI-L (16.4%) and MSS (56.7%) (20) while in study of (21) Microsatellite instability analysis showed (20.8%), MSS 58.4%, MSI-L 20.8%.

While in the study of (22) by used same Bethesda panel of sporadic CRCs in Czech patients the rate of MSI (20.4%), MSI L (3.9 %) and MSS (72.1%). in Italy patient with 10 markers used to detection MSI, the rate of MSI 25.0%, MSI L 29.5 % and MSS 45.5% In study of, (23) .

Some studies was shown less rate of MSI, in study of (24) the prevalence of MSI of sporadic CRC cases was 17%, and that of MSS was (83%), while in study of (25) was show MSI (14.73%), MSI L (8.21%) and MSS (77.05%) but in study of 756 patients from Omani patients were referred to (12.2%) the rate of MSI-H (26) In study (29) the rate of MSI-H (17.97%), MSI-L (12.58%) and MSS (68.53%).

Tumor classification is historically based on various clinical (eg, proximal versus distal), pathological (eg, mucinous versus nonmucinous; well-moderate versus poorly differentiated), and/or molecular features [eg, microsatellite instability status (MSI)-high versus microsatellite stable (MSS) (28) (29) (30)

This study close associated with female, old patients, right site, mucinous and poorly differentiation, because small number of patients some criteria appeared high percentage but not significant. According to the criteria, the results of current study was apperaed, MSI<sub>high</sub> in the femal high percentage 38.09% compated with male 34.61%, while the relation with age group the Group 2 ≤ 50 was shown high percentage 37.93% compated with Group 1 ≥50 33.33% and the realted of MSI with morphological feature was show the highly percentage in poor deffrrentated 47.07% compated with well and moderate. The mucinous MSI was revealed highly 4(4) with 100% pcentage compated with nonmucinous MSI 13(43) with 27.65% with siganficant defference. The site of tuomr with MSI was appeared high frequency in right site 52.94% with significant difference compared with MSI L and MSS.



This study agreement with (31) also observed this relationship when analyzed the location of tumors according to MSI status sporadic MSI are common in the proximal colon whereas MSI-L and MSS usually occur in the distal colon and the rectum, (20) (26) (32)

The MSI status was associated with right-sided location,(24). (33) (34) (35)

Significant relationships were seen between microsatellite instability, young and old age.(36) In microsatellite stable tumors observed significant relationships, increased age, (37)

Sporadic CRC with MSI-High molecular features have a distinct phenotype, they are more common in older women.(35)

MSI-H CRCs also tend to occur more frequently in female CRC patients and with earlier onset of disease (<50 years) (35) while most patients in the MSI-H group were females (26) (20) CRC have a propensity to develop on in older women. (24) (34) Significant relationships were seen between microsatellite instability and female gender (36)

Significant relationships were seen between microsatellite instability poor histological differentiation and MSI CRCs tend to have prominent poor differentiation.(32) (36).(38). These features are found in both familial and sporadic MSI-H CRC cases occur predominantly in the poor differentiation related with MSI (11) (32) (37). (39) (40).

Mucinous CRC, a subtype of CRC, is characterized by the abundant production of extracellular mucins and accounts for 5– 15% of all CRCs (41).

CRC have a propensity to develop in a mucinous phenotype (11) (32) (33) (34) (37) (39) (40). while significantly higher percentages of mucinous CRC had MSI or CIMP (24).( 26).

Pathological characteristics include increased lymphocytic infiltration (Crohn's disease-like reaction),.(11) (32) 33) (39) (40).

The high frequency of MSI-H suggests that should look at microsatellite instability prior to chemotherapy to determine the most appropriate chemotherapeutic strategy in our population.

With regard to MSI status and CRC patient survival, a systematic review of 32 studies that reported survival data on a total of 7642 colorectal cancer patients, including 1277 with MSI-H tumors, showed that MSI-H tumors were associated with better prognosis compared with MSS tumors (42) however, accumulating evidence has been suggested that MSI-high tumors are associated with good prognosis (43) (37)

CRC patients with MSI-H CRC status have better prognosis compared to non-MSI tumors, particularly among young patients (11) (33) (40) ( 44),( 45) (46)

### ***Molecular Correlates in CRC***

The role of MSI-L as a subtype of molecular changes in CRC is controversial and tumors showing it resemble MSS tumors in clinical features (11) (40) (47)

Similar to the MSI-H tumors, MSI-L tumors also tend to occur more commonly in proximal colon, but their gender and family history associations are more similar to the MSS tumors (48)

Whether MSI-low (MSI-L) exists as a distinct phenotype from MSS has been controversial (47) (49)

Thus, a newer MSI marker panel has been designed to separate a substantial number of MSI-L tumors into MSS and MSI-H (49) (50)

### **MSI Related With Frequency of Microsatellite Panel Genes.**

In this study the frequency of the microsatellite genes panel in all cases, the high percentage was recorded in BAT25 48.93%, while both BAT26, D5S346 was shown in 44.68%, while D17S250 was appeared in 19.14% and D2S123 in 25.23%.

Among MSI-H patients, instability in BAT-25 occurred in (83.3%), BAT 26 (72.2%), D2S123 in (61.1%) cases, D17S250 in (61.1%), and D5S346 in (44.4%).(20)

Samples positive for BAT25 instability (14%), BAT26, (21%) for BAT40, (18%) for D2S123, (16%) D17S250, and (14%) for D5S346.(21)

### **References**

- [1] Cunningham, D., Atkin, W., Lenz, H J., et al (2010). Colorectal cancer. Lancet 375:1030-47.
- [2] Jemal, A., Bray, F., Center, MM., et al (2011). Global cancer statistics. CA Cancer J Clin, 2011.
- [3] Van Steenberghe, LN., Elferink, MA., Krijnen, P. et al. (2010). Improved survival of colon cancer due to improved treatment and detection: a nation wide population-based study in The Netherlands 1989-2006. Ann Oncol; 21: 2206–2212.
- [4] Weitz, J., Koch, M., Debus J, et al (2005). Colorectal cancer. Lancet 365(9454): 153-165.
- [5] de la Chapelle, A. (2004). "Genetic predisposition to colorectal cancer." Nat Rev Cancer 4(10): 769-8.



- [6] Boland, CR. , Thibodeau, SN. , Hamilton, SR. et al. (1998). A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res*;58:5248-5257.
- [7] Karran, P. (1996). Microsatellite instability and DNA mismatch repair in human cancer. *Semin Cancer Biol*;7:15-24.
- [8] Jiricny, J.(2006). The multifaceted mismatch-repair system. *Nat Rev Mol Cell Biol*;7(5):335-46.
- [9] Poynter JN, Siegmund KD, Weisenberger DJ et al (2008) Molecular characterization of MSI-H colorectal cancer by MLH1 promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. *Cancer Epidemiol Biomark Prev* 17:3208–3215.
- [10] Iino, H., Simms, L., Young, J., et al (2000). DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary nonpolyposis colorectal cancer. *Gut*;47:37-42.
- [11] Boland, CR. & Goel, A. (2010). Microsatellite instability in colorectal cancer. *Gastroenterology* 138(6): 2073–2087.e3
- [12] Jass, JR. (2007). Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. *Histopathology*. Jan;50(1):113-30.
- [13] Guastadisegni C, Colafranceschi M, Ottini L, et al (2010). Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer . *Eur J Cancer*.Oct;46(15):2788-98.
- [14] Aaltonen LA. , Salovaara R. , Kristo P. , et al (1998). Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. *N Engl J Med* 338(21): 1481–1487.
- [15] Saiki RK. , Gelfand DH. , Stoffel S. , et al (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science* 239(4839):487–491.
- [16] Lothe RA. , Peltomaki P. , Meling GI. , et al (1993). Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. *Cancer Res* 53(24):5849–5852.
- [17] Peltomaki, P. (2003). Role of DNA mismatch repair defects in the pathogenesis of human cancer. *J Clin Oncol*;21(6):1174-9.
- [18] Grady, WM and Carethers, JM. (2008). Genomic and epigenetic instability in colorectal cancer pathogenesis. *Gastroenterology*;135(4):1079-99.
- [19] Ashktorab H. , Hassan Brim , Al-Riyami M. , et al (2008). Sporadic Colon Cancer: Mismatch Repair Immunohistochemistry and Microsatellite Instability in Omani Subjects. *Dig Dis Sci* 53:2723–2731.
- [20] Moghbeli M., Moaven O. , Dadkhah E. , et al (2011). High frequency of microsatellite instability in sporadic colorectal cancer patients in Iran. *Genet. Mol. Res.* 10 (4): 3520-3529.
- [21] Rasuck C. , Leite S. , Komatsuzaki F., et al (2012). Association between methylation in mismatch repair genes, V600E BRAF mutation and microsatellite instability in colorectal cancer patients. *Mol Biol Rep* (2012) 39:2553–2560.
- [22] Vasovcak P., Pavlikova K. , Sedlacek Z. et al (2011) Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients. *PLoS One* 6:e24114.
- [23] Agostini M. , Enzo MV. , Morandi L. et al (2010). A ten markers panel provides a more accurate and complete microsatellite instability analysis in mismatch repair-deficient colorectal tumors. *Cancer Biomark* 6:49–61.
- [24] Tanaka H., Deng G. , Matsuzaki K. , et al (2006). BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer *Int. J. Cancer*: 118, 2765–2771.
- [25] Ogino S., Kawasaki T., Kirkner G. et al., (2007). Evaluation of Markers for CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer by a Large Population-Based Sample. *Journal of Molecular Diagnostics*, Vol. 9, No. 3,
- [26] Ashktorab H. , Smoot D. , Farzanmehr H. , et al (2005). Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans *Int. J. Cancer*: 116, 914–919.
- [27] Ogino S., Odze RD., Kawasaki T., et al., (2006). Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. *Am J SurgPathol*, 30: 1175-1183.
- [28] Hamilton S. and Aaltonen, LA. (2000). Pathology and genetics of tumours of digestive system., World Health Organisation: New York.
- [29] Compton, C.C. (2003). Colorectal carcinoma: Diagnostic, prognostic, and molecular features. *Modern Pathology*,. 16(4): p. 376-388.



- [30] Redston, M. (2009). Epithelial Neoplasms of the Large Intestine. In: Odze RD &Goldblum JR (eds) Surgical pathology of the GI tract, liver, Biliary tract, and pancreas. Philadelphia, 597–637.
- [31] Stefanius K. (2011). Colorectal carcinogenesis via serrated route. Thesis PHD, University of Oulu, Faculty of Medicine.
- [32] Jenkins MA. , Hayashi S. , O'Shea AM. , et al (2007). Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a populationbased study. *Gastroenterology*;133(1):48-56.
- [33] Hawkins, NJ., Bariol, C., Ward, RL.(2002).The serrated neoplasia pathway. *Pathology*, 34: 548-555.
- [34] Costello JF., and Plass C: Methylation matters. *J Med Genet* 38:285-303, 2001
- [35] Iacopetta B, Grieu F, Amanuel B.( 2010). Microsatellite instability in colorectal cancer. *Asia Pac. J. Clin. Oncol.*; 6: 260–9. 78.
- [36] Samowitz WS. , Curtin K. , Ma KN. et al (2001) Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. *Cancer Epidemiol Biomarkers Prev* 10:917–923.
- [37] Samowitz W, Albertsen H, Herrick J, et al (2005). Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. *Gastroenterology* 129:837–845.
- [38] Jass JR (2004). HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. *Fam Cancer* 3:93–100.
- [39] Ruzkiewicz AR & Jass JR (2004) Microsatellite Instability in Colorectal Cancer: What, How, When, and Why? *Pathology Case Reviews* 9(4): 163–172.
- [40] Mäkinen MJ (2007) Colorectal serrated adenocarcinoma. *Histopathology* 50(1): 131–150.
- [41] Secco GB. , Fardelli R. , Campora E. , et al (1994). Primary mucinous adenocarcinomas and signet-ring cell carcinomas of colon and rectum. *Oncology*;51:30–4.
- [42] Popat, S., Hubner, R., Houlston, RS. (2005). Systematic review of microsatellite instability and colorectal cancer prognosis. *J ClinOncol*, 23: 609-618.
- [43] Ward RL. , Cheong K. , Ku SL. , et al (2003). Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. *J Clin Oncol* 21:3729–3736.
- [44] Barault L. , Charon-Barra C. , Jooste V. , et al (2008). Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. *Cancer Res* 68:8541–8546.
- [45] Gryfe R. , Kim H. , Hsieh ET. , et al (2000). Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. *N Engl J Med*;342(2):69-77.
- [46] Wright CM. , Dent OF. , Barker M., et al (200). Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. *Br J Surg.*;87(9):1197-202
- [47] Tomlinson I. , Halford S. , Aaltonen L. , et al (2002). Does MSI-low exist? *J Pathol* 197(1): 6–13.
- [48] Bapat B. , Lindor NM. , Baron J. , et al.(2009). The association of tumor microsatellite instability phenotype with family history of colorectal cancer. *Cancer Epidemiol Biomarkers Prev*;18(3):967-75.
- [49] Bacher JW. , Flanagan LA. , Smalley RL. , et al (2004). Development of a fluorescent multiplex assay for detection of MSI-High tumors. *Dis Markers*, 20:237–250.
- [50] Murphy KM. , Zhang S. , Geiger T. , et al (2006). Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. *J Mol Diagn*, 8:305–311.